Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27468627 | 0.99 | PTGS2 (0.47) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL27462731 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1LMNANPSR1L3MBTL1 | |
| SCHEMBL5210203 | 0.85 | LMNA (0.41) | PTGS2PTGS1LMNANPSR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27483154 | 0.85 | PTGS2 (0.49) | PTGS2PTGS1LMNANPSR1L3MBTL1 | |
| SCHEMBL27466767 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL27482777 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1LMNANPSR1L3MBTL1 | |
| SCHEMBL27552978 | 0.82 | PTGS2 (0.53) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL27482775 | 0.82 | PTGS2 (0.45) | PTGS2PTGS1MAPK14LMNANPSR1 | |
| SCHEMBL27480892 | 0.81 | L3MBTL1 (0.44) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL27466276 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1152863-C | Substituted pyridines as selective cyclooxygenase-2 inhibitors | ��˸���˹��(���ô�)��˾ | 2004-06-09 | — | — | CN | claimed |
| CN-1225085-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1999-08-04 | — | — | CN | claimed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11993602-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11981701-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-14 | — | — | US | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11932854-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3833667-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-115003303-B | PRMT5 inhibitors | 默沙东公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-115087638-B | PRMT5 inhibitors | 默沙东公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230348904-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2023-11-02 | — | — | US | disclosed |
| WO-2006068933-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006007496-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| EP-1303271-A4 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | UPJOHN CO (US) | 2004-09-01 | — | — | EP | disclosed |
| CN-1152863-C | Substituted pyridines as selective cyclooxygenase-2 inhibitors | ��˸���˹��(���ô�)��˾ | 2004-06-09 | — | — | CN | disclosed |
| EP-1303271-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1299123-A2 | USE OF COX-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS | Pharmacia Corporation (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002005848-A2 | USE OF COX-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| CN-1225085-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1999-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932854-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SNRPE, AGO2, SIN3A | PTGS2 1332/4885PTGS1 1184/4885ABCC4 4237/4885 |
| US-11981701-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PTGS2 3813/4885PTGS1 3422/4885ABCC4 2616/4885 |
| US-11993602-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PTGS2 3669/4885PTGS1 3063/4885ABCC4 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.